COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
a study on Cancer, General Ovarian Cancer Breast Cancer Lung Cancer Endometrial Cancer Triple-Negative Breast Cancer Lung Tumor Malignant Neoplasm Colorectal Cancer Rectal Cancer Solid Tumor Neoplasms
Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer, PVRIG, checkpoint inhibitor, DNAM (DNAX Accessory molecule 1), PD-1 inhibitor, CD112, CD 112R, Poliovirus receptor-related immunoglobulin, PVRL2, Nivolumab, opdivo, TIGIT antibody, COM902, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Lung Neoplasms, COM701, COM701 with Opdivo (Nivolumab).
- in progress, not accepting new patients
- Start Date
- Completion Date
- Compugen Ltd
- Phase 1 research study
- Study Type
- Expecting 140 study participants
- Last Updated